Table 1.
Patient and tumor characteristics.
| Population | All 141 (100) |
NLR < 4 121 (85.8) |
NLR ≥ 4 20 (14.2) |
p |
CRP < 5 90 (63.8) |
CRP ≥ 5 51 (36.2) |
p |
|---|---|---|---|---|---|---|---|
| Gender: Male | 80 (56.7) | 68 (56.2) | 12 (60) | 0.81 | 42 (46.7) | 38 (74.5) | 0.002 |
| Age at Surgery | 66 (IQR 59–71) | 67 (IQR 59–70) | 64.5 (IQR 59–73) | >0.99 | 67 (IQR 59–72) | 64 (IQR 59–69) | 0.26 |
| ASA: | |||||||
| 2 | 94 (66.7) | 82 (67.8) | 12 (60) | 0.60 | 61 (67.8) | 33 (64.7) | 0.71 |
| 3 | 47 (32.9) | 39 (32.2) | 8 (40) | 29 (32.2) | 18 (35.3) | ||
| Comorbidities | |||||||
| Coronaropathy | 9 (6.3) | 8 (6.6) | 1 (5) | >0.99 | 6 (6.7) | 3 (5.9) | >0.99 |
| Arrhythmia | 8 (5.7) | 7 (5.8) | 1 (5) | >0.99 | 3 (3.3) | 5 (9.8) | 0.14 |
| Hypertension | 52 (36.9) | 43 (35.5) | 9 (45) | 0.45 | 29 (32.2) | 23 (45.1) | 0.15 |
| Previous Cancer | 34 (24.1) | 28 (23.1) | 6 (30) | 0.57 | 17 (18.9) | 17 (33.3) | 0.07 |
| Lung Disease | 17 (12.1) | 15 (12.4) | 2 (10) | >0.99 | 10 (11.1) | 7 (13.7) | 0.78 |
| Diabetes | 14 (9.9) | 11 (9.1) | 3 (15) | 0.42 | 6 (6.7) | 8 (15.7) | 0.14 |
| Chronic Renal Failure | 3 (2.1) | 2 (1.6) | 1 (5) | 0.37 | 2 (2.2) | 1 (2) | >0.99 |
| Liver Disease | 6 (4.3) | 6 (4.9) | 0 | 0.59 | 4 (4.4) | 2 (3.9) | >0.99 |
| Other | 31 (22.0) | 27 (22) | 4 (20) | >0.99 | 20 (22.2) | 11 (21.6) | >0.99 |
| Primary tumor | |||||||
| Colon-Rectum | 57 (40.4) | 51 (42.5) | 6 (30) | 0.33 | 36 (40) | 21 (41.2) | >0.99 |
| Melanoma | 12 (8.5) | 12 (9.9) | 0 | 0.21 | 6 (6.7) | 6 (11.8) | 0.35 |
| Uterus | 4 (2.8) | 3 (2.5) | 1 (5) | 0.46 | 4 (4.4) | 0 | 0.30 |
| Breast | 6 (4.3) | 4 (3.3) | 2 (10) | 0.20 | 5 (5.6) | 1 (2) | 0.41 |
| Head-Neck | 6 (4.3) | 6 (4.9) | 0 | 0.59 | 4 (4.4) | 2 (3.9) | >0.99 |
| NSCLC | 12 (8.5) | 9 (7.4) | 3 (15) | 0.37 | 5 (5.6) | 7 (13.7) | 0.12 |
| Kidney | 16 (11.3) | 14 (11.6) | 2 (10) | >0.99 | 11 (12.2) | 5 (9.8) | 0.78 |
| Sarcoma | 14 (9.9) | 10 (8.3) | 4 (20) | 0.11 | 10 (11.1) | 4 (7.8) | 0.77 |
| Other | 14 (9.9) | 12 (9.9) | 2 (10) | >0.99 | 9 (10) | 5 (9.8) | >0.99 |
| RT/CHT | |||||||
| Neoadjuvant | 21 (14.9) | 20 (16.5) | 1 (5) | 0.30 | 13 (14.4) | 8 (15.7) | >0.99 |
| Adjuvant | 88 (62.4) | 77 (63.6) | 11 (55) | 0.47 | 62 (68.9) | 26 (51) | 0.05 |
| Metastases | |||||||
| Synchronous | 14 (9.9) | 14 (11.6) | 0 | 0.22 | 11 (12.2) | 3 (5.9) | 0.38 |
| Size (mm) | 14 (IQR 10–25) | 13 (IQR 10–25) | 16 (IQR 10–30) | 0.24 | 13 (IQR 10–25) | 16 (IQR 10–30) | 0.24 |
| Number of Lesions | |||||||
| 1 | 105 (74.5) | 69 (76.7) | 36 (70.6) | 0.65 | 69 (76.7) | 36 (70.6) | 0.65 |
| 2 | 24 (17) | 12 (13.3) | 12 (23.5) | 12 (13.3) | 12 (23.5) | ||
| ≥3 | 12 (8.5) | 9 (10) | 3 (5.9) | 9 (10) | 3 (5.9) | ||
| Bilateral Nodules | 16 (11.3) | 11 (9.1) | 5 (25) | 0.053 | 11 (12.2) | 5 (9.8) | 0.79 |
| DFI (Months) | 30 (IQR 17–56) | 29 (IQR 16–49) | 46 (IQR 22–121) | 0.07 | 32.5 (IQR 18–61) | 23 (IQR 14–49) | 0.24 |
Values are expressed as n (%) or median (interquartile range). Abbreviations: ASA: American Society of Anesthesiologist Score, CHT: chemotherapy, DFI: disease-free interval, RT: radiotherapy.